CL2017001017A1 - Nuevos compuestos de metil-piperidina útiles para inhibir la sintasa-1 de prostaglandina microsomal e2 - Google Patents
Nuevos compuestos de metil-piperidina útiles para inhibir la sintasa-1 de prostaglandina microsomal e2Info
- Publication number
- CL2017001017A1 CL2017001017A1 CL2017001017A CL2017001017A CL2017001017A1 CL 2017001017 A1 CL2017001017 A1 CL 2017001017A1 CL 2017001017 A CL2017001017 A CL 2017001017A CL 2017001017 A CL2017001017 A CL 2017001017A CL 2017001017 A1 CL2017001017 A1 CL 2017001017A1
- Authority
- CL
- Chile
- Prior art keywords
- compounds useful
- methyl piperidine
- piperidine compounds
- prostaglandin synthase
- new methyl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Abstract
<p>LA PRESENTE INVENCIÓN SE REFIERE A COMPUESTOS DE FORMULA 1, O UNA SAL DEL MISMO FARMACÉUTICAMENTE ACEPTABLE, DONDE R, R1, Y G SON COMO SE DESCRIBEN EN LA PRESENTE; MÉTODOS PARA PREPARAR LOS COMPUESTOS; Y USO DE LOS COMPUESTOS PARA TRATAR DOLOR Y/O INFLAMACIÓN ASOCIADA CON ARTRITIS U OSTEOARTRITIS.</p>
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462072196P | 2014-10-29 | 2014-10-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2017001017A1 true CL2017001017A1 (es) | 2017-12-11 |
Family
ID=54478248
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2017001017A CL2017001017A1 (es) | 2014-10-29 | 2017-04-24 | Nuevos compuestos de metil-piperidina útiles para inhibir la sintasa-1 de prostaglandina microsomal e2 |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US9962375B2 (es) |
| EP (1) | EP3230278B1 (es) |
| JP (1) | JP6393830B2 (es) |
| KR (1) | KR101898829B1 (es) |
| CN (1) | CN107074829B (es) |
| AR (1) | AR102362A1 (es) |
| AU (1) | AU2015339644B2 (es) |
| CA (1) | CA2963321C (es) |
| CL (1) | CL2017001017A1 (es) |
| CY (1) | CY1122534T1 (es) |
| DK (1) | DK3230278T3 (es) |
| EA (1) | EA032428B1 (es) |
| ES (1) | ES2773439T3 (es) |
| HR (1) | HRP20200216T1 (es) |
| HU (1) | HUE047895T2 (es) |
| JO (1) | JO3581B1 (es) |
| LT (1) | LT3230278T (es) |
| MX (1) | MX2017005659A (es) |
| NZ (1) | NZ730724A (es) |
| PL (1) | PL3230278T3 (es) |
| PT (1) | PT3230278T (es) |
| RS (1) | RS59783B1 (es) |
| SI (1) | SI3230278T1 (es) |
| TW (1) | TWI605039B (es) |
| WO (1) | WO2016069376A1 (es) |
| ZA (1) | ZA201702198B (es) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR102361A1 (es) | 2014-10-29 | 2017-02-22 | Lilly Co Eli | Compuestos de metil-quinolina útiles para inhibir la sintasa-1 de prostaglandina microsomal e2 |
| AU2019206468A1 (en) * | 2018-01-09 | 2020-08-06 | Brigham Young University | Compositions and methods for treating pain with wogonin |
| CN108558806B (zh) * | 2018-05-31 | 2020-04-17 | 南京药石科技股份有限公司 | 一种5-氧代-四氢吡喃-3-羧酸酯的关键中间体及其制备方法 |
| WO2020061475A2 (en) * | 2018-09-21 | 2020-03-26 | The Johns Hopkins University | Compositions and methods for treating metabolic disorders |
| MX2021015452A (es) | 2019-06-25 | 2022-02-11 | Gilead Sciences Inc | Proteinas de fusion flt3l-fc y metodos de uso. |
| JP7371243B2 (ja) | 2019-10-18 | 2023-10-30 | フォーティ セブン， インコーポレイテッド | 骨髄異形成症候群及び急性骨髄性白血病を治療するための併用療法 |
| CN114599392A (zh) | 2019-10-31 | 2022-06-07 | 四十七公司 | 基于抗cd47和抗cd20的血癌治疗 |
| TWI778443B (zh) | 2019-11-12 | 2022-09-21 | 美商基利科學股份有限公司 | Mcl1抑制劑 |
| MX2022007930A (es) | 2019-12-24 | 2022-08-08 | Carna Biosciences Inc | Compuestos moduladores de diacilglicerol quinasa. |
| WO2021163064A2 (en) | 2020-02-14 | 2021-08-19 | Jounce Therapeutics, Inc. | Antibodies and fusion proteins that bind to ccr8 and uses thereof |
| AU2021264550A1 (en) | 2020-05-01 | 2022-11-17 | Gilead Sciences, Inc. | CD73 inhibiting 2,4-dioxopyrimidine compounds |
| TW202211917A (zh) * | 2020-08-21 | 2022-04-01 | 南韓商治納輔醫藥科技有限公司 | 對***素e2受體具有抑制活性的新穎化合物及其用途 |
| TW202302145A (zh) | 2021-04-14 | 2023-01-16 | 美商基利科學股份有限公司 | ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症 |
| US20220389394A1 (en) | 2021-05-18 | 2022-12-08 | Gilead Sciences, Inc. | METHODS OF USING FLT3L-Fc FUSION PROTEINS |
| WO2022271677A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| EP4359413A1 (en) | 2021-06-23 | 2024-05-01 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| CA3222439A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| AU2022299051A1 (en) | 2021-06-23 | 2023-12-07 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| AU2022375782A1 (en) | 2021-10-28 | 2024-05-02 | Gilead Sciences, Inc. | Pyridizin-3(2h)-one derivatives |
| AU2022376954A1 (en) | 2021-10-29 | 2024-05-02 | Gilead Sciences, Inc. | Cd73 compounds |
| AU2022417491A1 (en) | 2021-12-22 | 2024-05-23 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| WO2023122581A2 (en) | 2021-12-22 | 2023-06-29 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| TW202340168A (zh) | 2022-01-28 | 2023-10-16 | 美商基利科學股份有限公司 | Ｐａｒｐ７抑制劑 |
| WO2023178181A1 (en) | 2022-03-17 | 2023-09-21 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| US20230355796A1 (en) | 2022-03-24 | 2023-11-09 | Gilead Sciences, Inc. | Combination therapy for treating trop-2 expressing cancers |
| TW202345901A (zh) | 2022-04-05 | 2023-12-01 | 美商基利科學股份有限公司 | 用於治療結腸直腸癌之組合療法 |
| TW202400138A (zh) | 2022-04-21 | 2024-01-01 | 美商基利科學股份有限公司 | Ｋｒａｓ ｇ１２ｄ調節化合物 |
| WO2024006929A1 (en) | 2022-07-01 | 2024-01-04 | Gilead Sciences, Inc. | Cd73 compounds |
| WO2024064668A1 (en) | 2022-09-21 | 2024-03-28 | Gilead Sciences, Inc. | FOCAL IONIZING RADIATION AND CD47/SIRPα DISRUPTION ANTICANCER COMBINATION THERAPY |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6355010B1 (en) * | 1999-03-31 | 2002-03-12 | Coaxia, Inc. | Intravascular spinal perfusion and cooling for use during aortic surgery |
| EP2281823A3 (en) | 2003-05-20 | 2011-09-07 | Ajinomoto Co., Inc. | Anti-inflammatory and analgesic piperidine derivatives |
| US20050239921A1 (en) * | 2004-04-27 | 2005-10-27 | Birmingham John N | Preparation of organic additive-treated, pyrogenic silica-encapsulated titanium dioxide particles |
| UY32470A (es) * | 2009-03-05 | 2010-10-29 | Boehringer Ingelheim Int | Derivados de 2-{2-cloro-5-[(sustituido) metil]fenilamino} -1-metil]fenilamino}-1-metilbencimidazol-5-carboxamidas-n-(sustituidas) y sus sales fisiológicamente aceptables, composiciones conteniéndolos y aplicaciones |
| WO2011023812A1 (en) | 2009-08-27 | 2011-03-03 | Novasaid Ab | Microsomal prostaglandin e synthase-1 (mpges1) inhibitors |
| JP5579862B2 (ja) * | 2009-10-23 | 2014-08-27 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ミクロソームプロスタグランジンｅ２シンターゼ−１のインヒビター |
| WO2013146970A1 (ja) * | 2012-03-29 | 2013-10-03 | 第一三共株式会社 | 新規キノリン誘導体 |
| JP2016522253A (ja) * | 2013-06-20 | 2016-07-28 | ノヴァサイド・アクチボラグ | Ｍｐｇｅ−１阻害剤としてのピペリジニルベンゾイミダゾール誘導体 |
| AR102361A1 (es) | 2014-10-29 | 2017-02-22 | Lilly Co Eli | Compuestos de metil-quinolina útiles para inhibir la sintasa-1 de prostaglandina microsomal e2 |
-
2015
- 2015-10-18 JO JOP/2015/0256A patent/JO3581B1/ar active
- 2015-10-19 TW TW104134250A patent/TWI605039B/zh active
- 2015-10-19 AR ARP150103382A patent/AR102362A1/es unknown
- 2015-10-22 NZ NZ730724A patent/NZ730724A/en unknown
- 2015-10-22 EA EA201790766A patent/EA032428B1/ru not_active IP Right Cessation
- 2015-10-22 JP JP2017522866A patent/JP6393830B2/ja active Active
- 2015-10-22 MX MX2017005659A patent/MX2017005659A/es active IP Right Grant
- 2015-10-22 PT PT157914326T patent/PT3230278T/pt unknown
- 2015-10-22 ES ES15791432T patent/ES2773439T3/es active Active
- 2015-10-22 HU HUE15791432A patent/HUE047895T2/hu unknown
- 2015-10-22 LT LTEP15791432.6T patent/LT3230278T/lt unknown
- 2015-10-22 CN CN201580058595.9A patent/CN107074829B/zh active Active
- 2015-10-22 CA CA2963321A patent/CA2963321C/en active Active
- 2015-10-22 RS RS20200015A patent/RS59783B1/sr unknown
- 2015-10-22 EP EP15791432.6A patent/EP3230278B1/en active Active
- 2015-10-22 WO PCT/US2015/056960 patent/WO2016069376A1/en active Application Filing
- 2015-10-22 DK DK15791432.6T patent/DK3230278T3/da active
- 2015-10-22 US US15/520,462 patent/US9962375B2/en active Active
- 2015-10-22 AU AU2015339644A patent/AU2015339644B2/en active Active
- 2015-10-22 PL PL15791432T patent/PL3230278T3/pl unknown
- 2015-10-22 SI SI201531036T patent/SI3230278T1/sl unknown
- 2015-10-22 KR KR1020177011303A patent/KR101898829B1/ko active IP Right Grant
-
2017
- 2017-03-29 ZA ZA2017/02198A patent/ZA201702198B/en unknown
- 2017-04-24 CL CL2017001017A patent/CL2017001017A1/es unknown
-
2018
- 2018-05-07 US US15/972,699 patent/US20180250282A1/en not_active Abandoned
-
2020
- 2020-01-29 CY CY20201100076T patent/CY1122534T1/el unknown
- 2020-02-11 HR HRP20200216TT patent/HRP20200216T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2017001017A1 (es) | Nuevos compuestos de metil-piperidina útiles para inhibir la sintasa-1 de prostaglandina microsomal e2 | |
| CL2017001050A1 (es) | Nuevos compuestos de metil-quinolina útiles para inhibir la sintasa-1 de prostaglandina microsomal e2 | |
| ECSP20005581A (es) | Compuestos y composiciones para tratar afecciones asociadas con la actividad nlrp | |
| CR20170237A (es) | Nuevos compuestos de 5-amino-6h-tiazolo[4,5-d]pirimidin-2,7-diona 3-sustituidos para el tratamiento y profilaxis de infecciones virales. | |
| EA201691085A1 (ru) | Замещенные бензамиды и способы их применения | |
| DOP2016000085A (es) | Amino-heteroaril-benzamidas como inhibidores de cinasa | |
| ES2721001T3 (es) | Derivado de isoindolina, y composiciones y métodos para tratar una enfermedad neurodegenerativa | |
| CR20160564A (es) | Dinucleótidos cíclicos como moduladores de sting | |
| CO2018000589A2 (es) | Oxiesteroles y composiciones farmacéuticas que los contienen | |
| CR20180201A (es) | Modularores del receptor x farnesoide | |
| DOP2017000034A (es) | Compuestos de imidazopiridazina | |
| UY34750A (es) | ?compuestos para el tratamiento del hiv, composiciones,métodos de preparación, intermediarios y métodos terapéuticos?. | |
| EA201692521A1 (ru) | Пиразольные соединения и их применение в качестве блокаторов кальциевых каналов т-типа | |
| CO2018012002A2 (es) | Compuestos de tipo tetrahidropirimidodiazepina y dihidropiridodiazepina para tratar el dolor y afecciones relacionadas con el dolor | |
| CU20160140A7 (es) | CROMENE Y 1,1 A,2,7B- tetrahidrociclopropa[C]CROMENE PIRIDOPIRAZINEDIONES COMO MODULADORES DE GAMMA-SECRETASA | |
| CR20160016A (es) | Pirazolpiridinas sustituidas | |
| CU20160148A7 (es) | Compuestos de azol sustituidos con amida como inhibidores de tnks1 y/o tnks2 | |
| AR105821A1 (es) | COMPUESTOS ÚTILES PARA INHIBIR ROR-g-T | |
| CU20170153A7 (es) | Compuestos tricíclicos útiles como inhibidores de la fosfodiesterasa | |
| EA201790613A8 (ru) | Триазольные соединения в качестве блокаторов кальциевых каналов т-типа | |
| CO2019001644A2 (es) | Derivado de triazolopirazinona útil como un inhibidor de pde1 humana | |
| CL2017000242A1 (es) | Compuestos de imidazopiridazina | |
| AR108363A1 (es) | Compuestos de tetrahidrofurooxazina y su uso como inhibidores de bace1 selectivos | |
| EA201892188A1 (ru) | Соединения пирролотриазина в качестве ингибиторов tam | |
| GT201500232A (es) | Compuestos de azabencimidazol como inhibidores de las isozimas pde4 para el tratamiento de cns y otros trastornos |